Supplementary Figure S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Key Points

• The AALL1331 study design effectively organizes treatment for both high/intermediate and low-risk cohorts.
• Blinatumomab plays a vital role in treating acute lymphoblastic leukemia within the chemotherapy consolidation phase.
• The study emphasizes differences in risk cohorts in response to treatment protocols during the trial.
• Understanding the AALL1331 design aids in comprehending outcomes for patients with acute lymphoblastic leukemia.